{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:52:02Z","timestamp":1773017522316,"version":"3.50.1"},"reference-count":61,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)","doi-asserted-by":"publisher","award":["514598620"],"award-info":[{"award-number":["514598620"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung (IZKF, Interdisciplinary Center for Clinical Research)","award":["514598620"],"award-info":[{"award-number":["514598620"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>NUT (nuclear-protein-in-testis) carcinoma (NC) is a highly aggressive tumor disease. Given that current treatment regimens offer a median survival of six months only, it is likely that this type of tumor requires an extended multimodal treatment approach to improve prognosis. In an earlier case report, we could show that an oncolytic herpes simplex virus (T-VEC) is functional in NC patients. To identify further combination partners for T-VEC, we have investigated the anti-tumoral effects of T-VEC and five different small molecule inhibitors (SMIs) alone and in combination in human NC cell lines. Dual combinations were found to result in higher rates of tumor cell reductions when compared to the respective monotherapy as demonstrated by viability assays and real-time tumor cell growth monitoring. Interestingly, we found that the combination of T-VEC with SMIs resulted in both stronger and earlier reductions in the expression of c-Myc, a main driver of NC cell proliferation, when compared to T-VEC monotherapy. These results indicate the great potential of combinatorial therapies using oncolytic viruses and SMIs to control the highly aggressive behavior of NC cancers and probably will pave the way for innovative multimodal clinical studies in the near future.<\/jats:p>","DOI":"10.3390\/v16050775","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T10:26:36Z","timestamp":1715682396000},"page":"775","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors"],"prefix":"10.3390","volume":"16","author":[{"given":"Stavros","family":"Sotiriadis","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-8249","authenticated-orcid":false,"given":"Julia","family":"Beil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership between DKFZ and University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Berchtold","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Smirnow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich M.","family":"Lauer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership between DKFZ and University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pin.12727","article-title":"NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/cncy.21761","article-title":"Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients","volume":"124","author":"Bishop","year":"2016","journal-title":"Cancer Cytopathol."},{"key":"ref_3","first-page":"304","article-title":"BRD4-NUT fusion oncogene: A novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.22838","article-title":"Emerging entities in NUTM1-rearranged neoplasms","volume":"59","author":"McEvoy","year":"2020","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1200\/JCO.2004.02.107","article-title":"Midline carcinoma of children and young adults with NUT rearrangement","volume":"22","author":"French","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)63049-0","article-title":"BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)","volume":"159","author":"French","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: A family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","article-title":"NSD3-NUT fusion oncoprotein in NUT midline carcinoma: Implications for a novel oncogenic mechanism","volume":"4","author":"French","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nsmb.2912","article-title":"BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones","volume":"21","author":"Kanno","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1097-2765(03)00482-9","article-title":"Selective recognition of acetylated histones by bromodomain proteins visualized in living cells","volume":"13","author":"Kanno","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E4184","DOI":"10.1073\/pnas.1702086114","article-title":"Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma","volume":"114","author":"Alekseyenko","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1074\/jbc.M707603200","article-title":"The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase","volume":"283","author":"Mochizuki","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/onc.2013.126","article-title":"MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma","volume":"33","author":"Grayson","year":"2014","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nm.3665","article-title":"A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia","volume":"20","author":"Herranz","year":"2014","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-15-1449","article-title":"Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition","volume":"22","author":"Henssen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/a-1026-6561","article-title":"Nuclear protein in testis (NUT) midline carcinoma","volume":"192","author":"Baumgartner","year":"2020","journal-title":"Rofo"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"914031","DOI":"10.3389\/fonc.2022.914031","article-title":"NUT Carcinoma-An Underdiagnosed Malignancy","volume":"12","author":"Lauer","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"pkz094","DOI":"10.1093\/jncics\/pkz094","article-title":"An Anatomical Site and Genetic-Based Prognostic Model for Patients with Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00405-018-4882-y","article-title":"Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: A systematic review and individual patient data analysis of 119 cases","volume":"275","author":"Giridhar","year":"2018","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-22-0591","article-title":"Report of the First International Symposium on NUT Carcinoma","volume":"28","author":"French","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ijc.33861","article-title":"Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I\/II open-label, dose escalation study","volume":"150","author":"Cousin","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2021.01.018","article-title":"Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE","volume":"146","author":"Pearson","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ohnesorge, P.V., Berchtold, S., Beil, J., Haas, S.A., Smirnow, I., Schenk, A., French, C.A., Luong, N.M., Huang, Y., and Fehrenbacher, B. (2022). Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14112761"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"995744","DOI":"10.3389\/fonc.2022.995744","article-title":"Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma","volume":"12","author":"Kloker","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1089\/hum.2017.138","article-title":"Virotherapy Research in Germany: From Engineering to Translation","volume":"28","author":"Ungerechts","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2015.10.004","article-title":"Oncolytic Viruses: Exploiting Cancer\u2019s Deal with the Devil","volume":"1","author":"Pikor","year":"2015","journal-title":"Trends Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2217\/fon-2022-0440","article-title":"Oncolytic viruses: Challenges and considerations in an evolving clinical landscape","volume":"18","author":"Lauer","year":"2022","journal-title":"Future Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/imt-2019-0033","article-title":"Talimogene laherparepvec: Review of its mechanism of action and clinical efficacy and safety","volume":"11","author":"Raman","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1634\/theoncologist.2018-0477","article-title":"Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study","volume":"24","author":"Jung","year":"2019","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-10-3513","article-title":"Differentiation of NUT midline carcinoma by epigenomic reprogramming","volume":"71","author":"Schwartz","year":"2011","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1038\/emboj.2010.176","article-title":"Oncogenesis by sequestration of CBP\/p300 in transcriptionally inactive hyperacetylated chromatin domains","volume":"29","author":"Reynoird","year":"2010","journal-title":"EMBO J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1535-7163.MCT-16-0390","article-title":"Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers","volume":"16","author":"Sun","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1038\/s41388-020-1301-9","article-title":"Therapeutic targeting of p300\/CBP HAT domain for the treatment of NUT midline carcinoma","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-20-0087","article-title":"Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734","volume":"19","author":"Knox","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1101\/gad.315648.118","article-title":"Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4\/6is","volume":"32","author":"Liao","year":"2018","journal-title":"Genes Dev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/s41467-022-32087-5","article-title":"Targeting the Retinoblastoma\/E2F repressive complex by CDK4\/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus","volume":"13","author":"Koch","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","article-title":"c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer","volume":"23","author":"Nebbioso","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1158\/1541-7786.MCR-21-0259","article-title":"Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment","volume":"19","author":"Shiota","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000500159","article-title":"The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines","volume":"109","author":"Kloker","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_43","unstructured":"Green, M.R., and Sambrook, J. (2012). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press."},{"key":"ref_44","unstructured":"Harlow, E., and Lane, D. (1988). Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"13028","DOI":"10.1073\/pnas.0701953104","article-title":"Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation","volume":"104","author":"Wu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.1128\/JVI.78.18.9689-9696.2004","article-title":"VP16-dependent association of chromatin-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection","volume":"78","author":"Herrera","year":"2004","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1128\/JVI.74.14.6287-6299.2000","article-title":"Evidence that herpes simplex virus VP16 is required for viral egress downstream of the initial envelopment event","volume":"74","author":"Mossman","year":"2000","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0378-1119(01)00512-1","article-title":"Regulation of herpes simplex virus gene expression","volume":"271","author":"Weir","year":"2001","journal-title":"Gene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1093\/nar\/19.18.4879","article-title":"Activation of the cellular transcription factor AP-1 in herpes simplex virus infected cells is dependent on the viral immediate-early protein ICPO","volume":"19","author":"Jang","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1074\/jbc.274.8.5097","article-title":"Herpes simplex virus type 1 infection stimulates p38\/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1","volume":"274","author":"Zachos","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1073\/pnas.0802785105","article-title":"Activation of PI3K\/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1","volume":"105","author":"Zhu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1038\/sj.emboj.7600279","article-title":"Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins","volume":"23","author":"Bouchard","year":"2004","journal-title":"EMBO J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1128\/MCB.01789-06","article-title":"Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression","volume":"27","author":"Delpuech","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/MCB.25.5.1608-1619.2005","article-title":"Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas","volume":"25","author":"Duan","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.0505585102","article-title":"Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim","volume":"102","author":"Zhao","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4161\/cc.8.4.7609","article-title":"Balancing the decision of cell proliferation and cell fate","volume":"8","author":"Hallstrom","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1074\/jbc.R100063200","article-title":"Signaling networks that link cell proliferation and cell fate","volume":"277","author":"Sears","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4161\/cc.2.4.428","article-title":"E2F1 and c-Myc in cell growth and death","volume":"2","author":"Matsumura","year":"2003","journal-title":"Cell Cycle"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/viro.1999.9755","article-title":"Herpes simplex virus induces intracellular redistribution of E2F4 and accumulation of E2F pocket protein complexes","volume":"258","author":"Olgiate","year":"1999","journal-title":"Virology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cgt.2008.81","article-title":"The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells","volume":"16","author":"Katsura","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1158\/0008-5472.CAN-23-2545","article-title":"The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma","volume":"83","author":"Durall","year":"2023","journal-title":"Cancer Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/5\/775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:55Z","timestamp":1760107315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/5\/775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["v16050775"],"URL":"https:\/\/doi.org\/10.3390\/v16050775","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]}}}